{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:16:34Z","timestamp":1774869394397,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T00:00:00Z","timestamp":1336608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00702-012-0815-x","type":"journal-article","created":{"date-parts":[[2012,5,8]],"date-time":"2012-05-08T22:05:23Z","timestamp":1336514723000},"page":"1351-1359","source":"Crossref","is-referenced-by-count":3,"title":["The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice"],"prefix":"10.1007","volume":"119","author":[{"given":"Karl","family":"Strecker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Adamaszek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Ohm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,10]]},"reference":[{"issue":"3","key":"815_CR1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/syn.20195","volume":"58","author":"T Antonelli","year":"2005","unstructured":"Antonelli T, Fuxe K, Tomasini MC, Bartoszyk GD, Seyfried CA, Tanganelli S, Ferraro L (2005) Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58(3):193\u2013199","journal-title":"Synapse"},{"issue":"8","key":"815_CR2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","volume":"38","author":"NM Barnes","year":"1999","unstructured":"Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38(8):1083\u20131152","journal-title":"Neuropharmacology"},{"issue":"Suppl 4","key":"815_CR3","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1353-8020(09)70827-2","volume":"15","author":"A Berthet","year":"2009","unstructured":"Berthet A, Bezard E (2009) Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism Relat Disord 15(Suppl 4):S8\u2013S12","journal-title":"Parkinsonism Relat Disord"},{"key":"815_CR4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.brainres.2007.11.017","volume":"1190","author":"J Blundell","year":"2008","unstructured":"Blundell J, Hoang CV, Potts B, Gold SJ, Powell CM (2008) Motor coordination deficits in mice lacking RGS9. Brain Res 1190:78\u201385","journal-title":"Brain Res"},{"issue":"1","key":"815_CR5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","volume":"17","author":"V Bonifati","year":"1994","unstructured":"Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G (1994) Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 17(1):73\u201382","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"815_CR6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0091-3057(99)00072-6","volume":"64","author":"F Borsini","year":"1999","unstructured":"Borsini F, Brambilla A, Grippa N, Pitsikas N (1999) Behavioral effects of flibanserin (BIMT 17). Pharmacol Biochem Behav 64(1):137\u2013146","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"815_CR7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1527-3458.2002.tb00219.x","volume":"8","author":"F Borsini","year":"2002","unstructured":"Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S (2002) Pharmacology of flibanserin. CNS Drug Rev 8(2):117\u2013142","journal-title":"CNS Drug Rev"},{"issue":"20","key":"815_CR8","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1212\/01.wnl.0000312279.49272.9f","volume":"70","author":"H Braak","year":"2008","unstructured":"Braak H, Del Tredici K (2008) Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70(20):1916\u20131925","journal-title":"Neurology"},{"issue":"8","key":"815_CR9","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.20612","volume":"20","author":"JM Brotchie","year":"2005","unstructured":"Brotchie JM (2005) Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20(8):919\u2013931","journal-title":"Mov Disord"},{"issue":"46","key":"815_CR10","doi-asserted-by":"crossref","first-page":"16339","DOI":"10.1073\/pnas.0407416101","volume":"101","author":"TM Cabrera-Vera","year":"2004","unstructured":"Cabrera-Vera TM, Hernandez S, Earls LR, Medkova M, Sundgren-Andersson AK, Surmeier DJ, Hamm HE (2004) RGS9-2 modulates D2 dopamine receptor-mediated Ca2+ channel inhibition in rat striatal cholinergic interneurons. Proc Natl Acad Sci USA 101(46):16339\u201316344","journal-title":"Proc Natl Acad Sci USA"},{"key":"815_CR11","doi-asserted-by":"crossref","unstructured":"Castro JPMV, Frussa-Filho R, Fukushiro DF, Silva RH, Medrano WA, Ribeiro R de A, Ab\u00edlio VC (2006) Effects of baclofen on reserpine-induced vacuous chewing movements in mice. Brain Res Bull 68(6):436\u2013441","DOI":"10.1016\/j.brainresbull.2005.09.019"},{"issue":"Suppl 1","key":"815_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199855001-00001","volume":"55","author":"TN Chase","year":"1998","unstructured":"Chase TN (1998) The significance of continuous dopaminergic stimulation in the treatment of Parkinson\u2019s disease. Drugs 55(Suppl 1):1\u20139","journal-title":"Drugs"},{"issue":"6769","key":"815_CR13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/35000601","volume":"403","author":"CK Chen","year":"2000","unstructured":"Chen CK, Burns ME, He W, Wensel TG, Baylor DA, Simon MI (2000) Slowed recovery of rod photoresponse in mice lacking the GTPase accelerating protein RGS9-1. Nature 403(6769):557\u2013560","journal-title":"Nature"},{"issue":"5","key":"815_CR14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/whe.10.54","volume":"6","author":"AH Clayton","year":"2010","unstructured":"Clayton AH, Dennerstein L, Pyke R, Sand M (2010) Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women. Women\u2019s Health (Lond Engl) 6(5):639\u2013653","journal-title":"Women\u2019s Health (Lond Engl)"},{"issue":"2\u20133","key":"815_CR15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(97)01412-X","volume":"340","author":"P D\u2019Aquila","year":"1997","unstructured":"D\u2019Aquila P, Monleon S, Borsini F, Brain P, Willner P (1997) Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant. Eur J Pharmacol 340(2\u20133):121\u2013132","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"815_CR16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.brainresbull.2005.12.009","volume":"69","author":"A Dekundy","year":"2006","unstructured":"Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W (2006) Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson\u2019s disease. Brain Res Bull 69(3):318\u2013326","journal-title":"Brain Res Bull"},{"issue":"1","key":"815_CR17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","volume":"179","author":"A Dekundy","year":"2007","unstructured":"Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179(1):76\u201389","journal-title":"Behav Brain Res"},{"issue":"Suppl 4","key":"815_CR18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00415-008-4006-5","volume":"255","author":"F Sorbo Del","year":"2008","unstructured":"Del Sorbo F, Albanese A (2008) Levodopa-induced dyskinesias and their management. J Neurol 255(Suppl 4):32\u201341","journal-title":"J Neurol"},{"issue":"4","key":"815_CR19","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","volume":"164","author":"S Duty","year":"2011","unstructured":"Duty S, Jenner P (2011) Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease. British J Pharmacol 164(4):1357\u20131391","journal-title":"British J Pharmacol"},{"issue":"3","key":"815_CR20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","volume":"87","author":"KL Eskow","year":"2007","unstructured":"Eskow KL, Gupta V, Alam S, Park JY, Bishop C (2007) The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 87(3):306\u2013314","journal-title":"Pharmacol Biochem Behav"},{"key":"815_CR21","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00702-010-0570-9","volume":"118","author":"M Gerlach","year":"2011","unstructured":"Gerlach M, Beck J, Riederer P, van den Buuse M (2011) Flibanserin attenuates l-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson\u2019s disease. J Neural Transm 118:1727\u20131732","journal-title":"J Neural Transm"},{"issue":"52","key":"815_CR22","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1523\/JNEUROSCI.4223-07.2007","volume":"27","author":"SJ Gold","year":"2007","unstructured":"Gold SJ, Hoang CV, Potts BW, Porras G, Pioli E, Kim KW, Nadjar A (2007) RGS9-2 negatively modulates l-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson\u2019s disease. J Neurosci 27(52):14338\u201314348","journal-title":"J Neurosci"},{"key":"815_CR23","unstructured":"Hammer \u00d8, Harper DAT, Ryan PD (2001) PAST: Paleontological statistics software package for education and data analysis. Palaeontologia Electronica 4(1)"},{"issue":"Suppl 11","key":"815_CR24","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","volume":"20","author":"J Jankovic","year":"2005","unstructured":"Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson\u2019s disease: clinical manifestations. Mov Disord 20(Suppl 11):S11\u2013S16","journal-title":"Mov Disord"},{"issue":"4","key":"815_CR25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/jnnp.54.4.376-a","volume":"54","author":"B Kleedorfer","year":"1991","unstructured":"Kleedorfer B, Lees AJ, Stern GM (1991) Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry 54(4):376\u2013377","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"815_CR26","first-page":"747","volume":"282","author":"MS Kleven","year":"1997","unstructured":"Kleven MS, Assi\u00e9 MB, Koek W (1997) Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist\/5-HT(2A\/2C) antagonist anxiolytics II drug discrimination and behavioral observation studies in rats. J Pharmacol Exp Therapeutics 282(2):747\u2013759","journal-title":"J Pharmacol Exp Therapeutics"},{"issue":"8","key":"815_CR27","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1523\/JNEUROSCI.2840-04.2005","volume":"25","author":"A Kovoor","year":"2005","unstructured":"Kovoor A, Seyffarth P, Ebert J, Barghshoon S, Chen CK, Schwarz S, Axelrod JD (2005) D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J Neurosci 25(8):2157\u20132165","journal-title":"J Neurosci"},{"issue":"45","key":"815_CR28","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1523\/JNEUROSCI.2959-05.2005","volume":"25","author":"AC Kreitzer","year":"2005","unstructured":"Kreitzer AC, Malenka RC (2005) Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci 25(45):10537\u201310545","journal-title":"J Neurosci"},{"key":"815_CR29","doi-asserted-by":"crossref","unstructured":"Kumar R, Riddle LR, Griffin SA, Chu W, Vangveravong S, Neisewander J, Mach RH (2009) Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology 56(6-7):956\u2013969","DOI":"10.1016\/j.neuropharm.2009.01.019"},{"issue":"1\u20132","key":"815_CR30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0304-3940(94)90957-1","volume":"179","author":"GJ LaHoste","year":"1994","unstructured":"LaHoste GJ, Marshall JF (1994) Rapid development of D1 and D2 dopamine receptor supersensitivity as indicated by striatal and pallidal Fos expression. Neurosci Lett 179(1\u20132):153\u2013156","journal-title":"Neurosci Lett"},{"issue":"1","key":"815_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568007043482570","volume":"3","author":"L Lanfumey","year":"2004","unstructured":"Lanfumey L, Hamon M (2004) 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord 3(1):1\u201310","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"815_CR32","doi-asserted-by":"crossref","unstructured":"Lenzer J (2010) Boehringer Ingelheim withdraws libido drug for women. BMJ (Clinical Research Ed) 341:c5701","DOI":"10.1136\/bmj.c5701"},{"key":"815_CR33","unstructured":"Liou Y-J, Chen M-L, Wang Y-C, Chen J-Y, Liao D-L, Bai Y-M, Lin C\u2013C (2009) Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia. Am J Med Genet Part B Neuropsychiatric Genet 150B(2):239\u2013242. doi: 101002\/ajmgb30796"},{"issue":"3","key":"815_CR34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0306-4522(00)00588-1","volume":"103","author":"A Lopez","year":"2001","unstructured":"Lopez A, Munoz A, Guerra MJ, Labandeira-Garcia JL (2001) Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 103(3):639\u2013651","journal-title":"Neuroscience"},{"issue":"1","key":"815_CR35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","volume":"194","author":"M Lundblad","year":"2005","unstructured":"Lundblad M, Usiello A, Carta M, H\u00e5kansson K, Fisone G, Cenci MA (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 194(1):66\u201375","journal-title":"Exp Neurol"},{"issue":"2","key":"815_CR36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-008-1452-9","volume":"204","author":"C Marin","year":"2009","unstructured":"Marin C, Aguilar E, Rodr\u00edguez-Oroz MC, Bartoszyk GD, Obeso JA (2009) Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology 204(2):241\u2013250","journal-title":"Psychopharmacology"},{"issue":"3","key":"815_CR37","first-page":"163","volume":"52","author":"MD Muenter","year":"1977","unstructured":"Muenter MD, Sharpless NS, Tyce GM, Darley FL (1977) Patterns of dystonia (\u201cI-D-I\u201d and \u201cD-I-D-\u201d) in response to l-dopa therapy for Parkinson\u2019s disease. Mayo Clin Proc Mayo Clin 52(3):163\u2013174","journal-title":"Mayo Clin Proc Mayo Clin"},{"issue":"1","key":"815_CR38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.expneurol.2009.05.033","volume":"219","author":"A Mu\u00f1oz","year":"2009","unstructured":"Mu\u00f1oz A, Carlsson T, Tronci E, Kirik D, Bj\u00f6rklund A, Carta M (2009) Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol 219(1):298\u2013307","journal-title":"Exp Neurol"},{"issue":"1\u20132","key":"815_CR39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2009.05.024","volume":"146","author":"Y Nagakura","year":"2009","unstructured":"Nagakura Y, Oe T, Aoki T, Matsuoka N (2009) Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia. Pain 146(1\u20132):26\u201333","journal-title":"Pain"},{"issue":"3","key":"815_CR40","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1124\/jpet.103.064626","volume":"309","author":"P Osei-Owusu","year":"2004","unstructured":"Osei-Owusu P, Scrogin KE (2004) Buspirone raises blood pressure through activation of sympathetic nervous system and by direct activation of alpha1-adrenergic receptors after severe hemorrhage. J Pharmacol Exp Therapeutics 309(3):1132\u20131140","journal-title":"J Pharmacol Exp Therapeutics"},{"issue":"5","key":"815_CR41","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","volume":"6","author":"B Picconi","year":"2003","unstructured":"Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA (2003) Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat Neurosci 6(5):501\u2013506","journal-title":"Nat Neurosci"},{"issue":"4","key":"815_CR42","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/sj.bjp.0703364","volume":"130","author":"J Podhorna","year":"2000","unstructured":"Podhorna J, Brown RE (2000) Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety. Br J Pharmacol 130(4):739\u2013746","journal-title":"Br J Pharmacol"},{"issue":"6","key":"815_CR43","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1523\/JNEUROSCI.19-06-02016.1999","volume":"19","author":"Z Rahman","year":"1999","unstructured":"Rahman Z, Gold SJ, Potenza MN, Cowan CW, Ni YG, He W, Wensel TG (1999) Cloning and characterization of RGS9-2: a striatal-enriched alternatively spliced product of the RGS9 gene. J Neurosci 19(6):2016\u20132026","journal-title":"J Neurosci"},{"issue":"6","key":"815_CR44","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0896-6273(03)00321-0","volume":"38","author":"Z Rahman","year":"2003","unstructured":"Rahman Z, Schwarz J, Gold SJ, Zachariou V, Wein MN, Choi KH, Kovoor A (2003) RGS9 modulates dopamine signaling in the basal ganglia. Neuron 38(6):941\u2013952","journal-title":"Neuron"},{"issue":"1","key":"815_CR45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1152\/physrev.1998.78.1.35","volume":"78","author":"DK Rohrer","year":"1998","unstructured":"Rohrer DK, Kobilka BK (1998) G protein-coupled receptors: functional and mechanistic insights through altered gene expression. Physiol Rev 78(1):35\u201352","journal-title":"Physiol Rev"},{"key":"815_CR46","doi-asserted-by":"crossref","unstructured":"Scholz B, Svensson M, Alm H, Sk\u00f6ld K, F\u00e4lth M, Kultima K, Guigoni C (2008) Striatal proteomic analysis suggests that first l-dopa dose equates to chronic exposure. PloS One 3(2):e1589","DOI":"10.1371\/journal.pone.0001589"},{"key":"815_CR47","doi-asserted-by":"crossref","unstructured":"Seeman P, Schwarz J, Chen J-F, Szechtman H, Perreault M, McKnight GS, Roder JC (2006) Psychosis pathways converge via D2high dopamine receptors. Synapse 60(4):319\u2013346","DOI":"10.1002\/syn.20303"},{"issue":"1","key":"815_CR48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1743-6109.2010.02032.x","volume":"8","author":"SM Stahl","year":"2011","unstructured":"Stahl SM, Sommer B, Allers KA (2011) Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med 8(1):15\u201327","journal-title":"J Sex Med"},{"key":"815_CR49","doi-asserted-by":"crossref","unstructured":"Strecker K, Wegner F, Hesse S, Becker G-A, Patt M, Meyer PM, Lobsien D (2011) Preserved serotonin transporter binding in de novo Parkinson\u2019s disease: negative correlation with the dopamine transporter. J Neurol 258(1):19\u201326","DOI":"10.1007\/s00415-010-5666-5"},{"issue":"1\u20133","key":"815_CR50","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2008.06.013","volume":"589","author":"M Tanabe","year":"2008","unstructured":"Tanabe M, Hashimoto M, Ono H (2008) Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson\u2019s disease. Eur J Pharmacol 589(1\u20133):102\u2013105","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"815_CR51","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","volume":"10","author":"H Tanaka","year":"1999","unstructured":"Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M (1999) Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. NeuroReport 10(3):631\u2013634","journal-title":"NeuroReport"},{"issue":"2","key":"815_CR52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neures.2005.03.004","volume":"52","author":"M Tomiyama","year":"2005","unstructured":"Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M (2005) A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to l-DOPA in a rodent model of Parkinson\u2019s disease. Neurosci Res 52(2):185\u2013194","journal-title":"Neurosci Res"},{"issue":"1","key":"815_CR54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/jpet.108.144097","volume":"328","author":"NP Visanji","year":"2009","unstructured":"Visanji NP, Fox SH, Johnston TH, Millan MJ, Brotchie JM (2009) Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. J Pharmacol Exper Therapeutics 328(1):276\u2013283","journal-title":"J Pharmacol Exper Therapeutics"},{"issue":"6","key":"815_CR55","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/j.1471-4159.2010.07061.x","volume":"115","author":"M Volta","year":"2010","unstructured":"Volta M, Mabrouk OS, Bido S, Marti M, Morari M (2010) Further evidence for an involvement of nociceptin\/orphanin FQ in the pathophysiology of Parkinson\u2019s disease: a behavioral and neurochemical study in reserpinized mice. J Neurochem 115(6):1543\u20131555","journal-title":"J Neurochem"},{"issue":"1","key":"815_CR56","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00213-005-0263-5","volume":"185","author":"JJ Wacan","year":"2006","unstructured":"Wacan JJ, Reichel CM, Farley CM, McDougall SA (2006) The partial dopamine D2-like receptor agonist terguride functions as an agonist in preweanling rats after a 5-day reserpine regimen. Psychopharmacology 185(1):104\u2013111","journal-title":"Psychopharmacology"},{"issue":"3","key":"815_CR57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neulet.2010.05.068","volume":"479","author":"L\u2013L Yin","year":"2010","unstructured":"Yin L\u2013L, Cao Y, Xie K-Q (2010) Decreased RGS9 protein level in the striatum of rodents undergoing MPTP or 6-OHDA neurotoxicity. Neurosci Lett 479(3):231\u2013235","journal-title":"Neurosci Lett"},{"key":"815_CR58","doi-asserted-by":"crossref","unstructured":"Zachariou V, Georgescu D, Sanchez N, Rahman Z, DiLeone R, Berton O, Neve RL (2003) Essential role for RGS9 in opiate action. Proc Natl Acad Sci USA 100(23):13656\u201313661","DOI":"10.1073\/pnas.2232594100"},{"issue":"4","key":"815_CR59","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11910-007-0046-y","volume":"7","author":"TA Zesiewicz","year":"2007","unstructured":"Zesiewicz TA, Sullivan KL, Hauser RA (2007) Levodopa-induced dyskinesia in Parkinson\u2019s disease: epidemiology, etiology, and treatment. Curr Neurol Neurosci Reports 7(4):302\u2013310","journal-title":"Curr Neurol Neurosci Reports"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-012-0815-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-012-0815-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-012-0815-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T08:05:43Z","timestamp":1561709143000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-012-0815-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,10]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["815"],"URL":"https:\/\/doi.org\/10.1007\/s00702-012-0815-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,10]]}}}